within Pharmacolibrary.Drugs.ATC.J;

model J02AC04_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00014583333333333335,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.27,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.167,
    k12             = 9.3,
    k21             = 9.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J02AC04_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Posaconazole is a triazole antifungal agent approved for the prevention and treatment of invasive fungal infections caused by Aspergillus and Candida species in immunocompromised patients. It is used both for prophylaxis in patients at high risk for fungal infections and for treatment of ongoing invasive infections. Approved by FDA and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, single-dose pharmacokinetics following 200 mg intravenous infusion over 30 minutes.</p><h4>References</h4><ol><li><p>Chen, L, et al., &amp; Brüggemann, RJM (2020). Pharmacokinetics and Pharmacodynamics of Posaconazole. <i>Drugs</i> 80(7) 671–695. DOI:<a href=&quot;https://doi.org/10.1007/s40265-020-01306-y&quot;>10.1007/s40265-020-01306-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32323222/&quot;>https://pubmed.ncbi.nlm.nih.gov/32323222</a></p></li><li><p>Sime, FB, et al., &amp; Roberts, JA (2018). Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. <i>Antimicrobial agents and chemotherapy</i> 62(6) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00242-18&quot;>10.1128/AAC.00242-18</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29581122/&quot;>https://pubmed.ncbi.nlm.nih.gov/29581122</a></p></li><li><p>Li, H, et al., &amp; Xie, S (2019). Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability. <i>Clinical drug investigation</i> 39(11) 1109–1116. DOI:<a href=&quot;https://doi.org/10.1007/s40261-019-00833-1&quot;>10.1007/s40261-019-00833-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31432392/&quot;>https://pubmed.ncbi.nlm.nih.gov/31432392</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J02AC04_1;
